Apnimed secures $192 million IPO to fund sleep-apnea drug program targeting 2027 launch

Apnimed, a biotech focused on sleep apnea, announced it raised $192 million through an initial public offering.

The capital will be used to advance its lead drug candidate, with plans to begin a launch in 2027 pending regulatory approval.

The IPO comes after more than three years of preparation for a Nasdaq listing, reflecting investor interest in the sleep-disorder market.